Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/19/2025 07:52 PDT] APLS, Expected to Trade Lower After Bearish Insider Trading
• [06/13/2025 07:01 PDT] sector Stocks Expected To Be Down After Top Correlated Stocks Fire Sell Signals.
• [05/21/2025 07:28 PDT] APLS Expected to Trade Up After Bullish Patterns Develop
• [05/16/2025 07:13 PDT] APLS Expected to Trade Down After Bearish Patterns Develop
• [05/08/2025 07:16 PDT] sector Stocks Expected To Be Down After Top Correlated Stocks Fire Sell Signals.